+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Thrombocythemia Myelofibrosis Drug"

Post-Essential Thrombocythemia Myelofibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Post-Essential Thrombocythemia Myelofibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 73 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

Thrombocythemia Myelofibrosis (TMF) is a rare type of leukemia that affects the bone marrow and blood cells. It is characterized by an overproduction of platelets, an enlarged spleen, and an accumulation of scar tissue in the bone marrow. Treatment for TMF includes chemotherapy, radiation therapy, and targeted therapies such as JAK inhibitors. The TMF drug market is a small but growing segment of the larger leukemia drug market. It is composed of a variety of drugs, including JAK inhibitors, chemotherapy agents, and other targeted therapies. These drugs are used to reduce platelet counts, reduce spleen size, and reduce scar tissue in the bone marrow. The TMF drug market is expected to grow in the coming years due to the increasing prevalence of the disease and the development of new treatments. Some companies in the TMF drug market include Novartis, Incyte, Celgene, and Gilead Sciences. Show Less Read more